ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Dr. Michael Birrer Treatments Targeting Either VEGF or ANG2 in Gynecologic Cancers

Michael Birrer, MD, PhD
Published Online:5:39 PM, Wed November 25, 2015

 

Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, on treatments targeting either VEGF or ANG2 in gynecologic cancers.

 

Birrer says VEGF stimulates tumor vessel growth, while ANG2 stabilizes the vessels, making both an attractive target for oncologists. Birrer adds that to date, ANG2-targeted therapies have not been as successful in trials as VEGF-targeted therapies. ANG2-targeted therapies have given patients a better progression-free survival, but the treatment has not affected patients’ overall survival rates, he says.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.